A scientist before his foray into business, Axio BioPharma co-founder Justin Byers found that promising drug concepts often faced daunting barriers to production at a large scale.
Now, his startup is working to maximize time- and cost-efficiency in Madison’s clinical manufacturing space.
The process of getting breakthrough drugs to pharmaceutical companies, and ultimately patients, in a reasonable time frame and at a palatable cost, is complicated, and Byers envisioned creating a more rapid and reliable approach.
As it develops artificial intelligence to inform manufacturing processes and ramp up the efficiency of clinical manufacturing, Axio BioPharma is working to attract investors and a strong client base.